The present invention provides a method for determining the onset possibility or disease activity of IgA nephropathy by means of blood-mediated liquid biopsy, in addition to highly invasive renal biopsy and conventionally used proteinuria or hematuria. The present invention provides a method for determining the onset possibility or disease activity of IgA nephropathy in a test animal, the method comprising (a) a step for measuring an IgA nephropathy marker protein contained in an IgA immune complex in a blood sample collected from the test animal, and (b) a step for determining the onset possibility or disease activity of IgA nephropathy in the test animal on the basis of the amount of the IgA nephropathy marker protein measured in step (a), wherein the IgA nephropathy marker protein is a protein which is contained in the IgA immune complex, and with which the amount of the IgA nephropathy marker protein contained in the IgA immune complex in an IgA nephropathy patient group is greater than the amount contained in the IgA immune complex of a healthy subject group.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
2.
URICASE ACTIVATOR AND URIC ACID MEASUREMENT REAGENT
Provided are a uricase activator and a uricase activation method which are capable of highly activating uricase. Also provided are a uric acid measurement reagent and a uric acid measurement method which have a wide measurable concentration range. Further provided are a uricase activator comprising hydroxyisourate hydrolase, and a uric acid measurement reagent for use in measuring a uric acid concentration in a sample collected from a living body, comprising uricase and hydroxyisourate.
C12N 9/78 - Hydrolases (3.) agissant sur les liaisons carbone-azote autres que les liaisons peptidiques (3.5)
C12Q 1/34 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase
Provided is a production method for obtaining pyridoxamine phosphate having high coenzyme activity with AST or ALT. For the production of pyridoxamine phosphate, pyridoxal kinase and pyridoxamine are brought into contact in the presence of adenosine triphosphate at a pyridoxamine concentration of 2 mM or more, and reacted until the percentage of pyridoxamine remaining is less than 5%.
C12P 17/12 - Préparation de composés hétérocycliques comportant O, N, S, Se ou Te comme uniques hétéro-atomes du cycle l'azote comme unique hétéro-atome du cycle contenant un hétérocycle à six chaînons
C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)
C12Q 1/52 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une transférase une transaminase
4.
COMPOUND COMPRISING BETA-NICOTINAMIDE MONONUCLEOTIDE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF, AND METHOD FOR EVALUATING QUALITY AND METHOD FOR ASSESSING ENZYMATIC REACTIVITY OF SAID COMPOUND
A compound includes β-nicotinamide mononucleotide or a pharmacologically acceptable salt thereof. A purity of the compound as measured through HPLC is 95% or higher. A reactivity of the compound with lactate dehydrogenase is 30 units or higher.
C12Q 1/32 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une oxydoréductase une déshydrogénase
B01D 15/08 - Adsorption sélective, p. ex. chromatographie
The present invention provides a cereal flour composition which contains a cereal flour and an enzyme belonging to the tannase family, and in which the tannase activity per 1 g of the cereal flour is 0.1 kU/g to 60 kU/g. The composition preferably includes, in terms of mass, 10 ppm to 10,000 ppm of the enzyme relative to the total amount of the cereal flour. The cereal flour preferably includes at least one selected from among whole-wheat flour, bran, and other cereal flours having an ash content of 0.7 mass% or higher. The ash content of the cereal flour is preferably 0.5 mass% or higher.
The present invention provides a cereal flour composition which contains a cereal flour and an enzyme belonging to the tannase family, and in which the tannase activity per 1 g of the cereal flour is 0.1 kU/g to 60 kU/g. The composition preferably includes, in terms of mass, 10 ppm to 10,000 ppm of the enzyme relative to the total amount of the cereal flour. The cereal flour preferably includes at least one selected from among whole-wheat flour, bran, and other cereal flours having an ash content of 0.7 mass% or higher. The ash content of the cereal flour is preferably 0.5 mass% or higher.
Provided are a method and composition for stabilising nicotinamide adenine dinucleotide (NAD) in a biosample. A sample derived from a subject is brought into contact with nicotinamide and/or nicotinamide derivative to stabilise NAD in the sample.
C12Q 1/26 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une oxydoréductase
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
A medium for stem cells according to the present invention contains at least one of carboxymethyl cellulose and polyvinylpyrrolidone as a water-soluble polymer. The content of carboxymethyl cellulose in the medium is preferably such that the final concentration thereof is 0.001 μg/mL to 1 mg/mL. The content of polyvinylpyrrolidone in the medium is preferably such that the final concentration thereof is 0.05 μg/mL to 2 mg/mL.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
The present invention provides a chromosome-stabilizing agent for stem cells containing a β-nicotinamide mononucleotide or a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. The present invention also provides a culture method for stem cells, including culturing stem cells in a culture medium containing a β-nicotinamide mononucleotide or a pharmaceutically acceptable salt thereof, or a solvate thereof.
An object of the present invention is to provide a material capable of further accelerating growth of pluripotent stem cells, such as pluripotent stem cells, without impairing pluripotency thereof. In other words, the invention is an agent for accelerating growth of pluripotent stem cells, containing a β-nicotinamide mononucleotide or a pharmaceutically acceptable salt thereof, and a solvate thereof as an active ingredient; and is a method for culturing pluripotent stem cells, including culturing pluripotent stem cells in a culture medium that contains a β-nicotinamide mononucleotide or a pharmaceutically acceptable salt thereof, and a solvate thereof.
Provided are a method for keeping qualities of cooked rice and a method for producing cooked rice, including a step of bringing a polyvalent cation-containing liquid into contact with rice at any timing between before and after rice boiling or rice steaming, and a step of bringing an alginate-containing liquid into contact with the rice that contains a polyvalent cation and has been boiled or steamed.
Provided are a uricase activator capable of high activation of uricase and a uricase activation method. Provided are a uric acid measurement reagent having a wide measurable concentration range and a uric acid measurement method. Provided are: a uricase activator that includes hydroxyisourate hydrolase; and a uric acid measurement reagent to be used to measure the uric acid concentration in a sample collected from a living organism, the uric acid measurement reagent including uricase and hydroxyisouric acid.
C12N 9/06 - Oxydoréductases (1.), p. ex. luciférase agissant sur des composés contenant de l'azote comme donneurs (1.4, 1.5, 1.7)
C12Q 1/26 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une oxydoréductase
C12Q 1/34 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
Provided are a uricase activator capable of high activation of uricase and a uricase activation method. Provided are a uric acid measurement reagent having a wide measurable concentration range and a uric acid measurement method. Provided are: a uricase activator that includes hydroxyisourate hydrolase; and a uric acid measurement reagent to be used to measure the uric acid concentration in a sample collected from a living organism, the uric acid measurement reagent including uricase and hydroxyisouric acid.
C12Q 1/26 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une oxydoréductase
C12Q 1/34 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase
C12N 9/06 - Oxydoréductases (1.), p. ex. luciférase agissant sur des composés contenant de l'azote comme donneurs (1.4, 1.5, 1.7)
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
The stem cell medium according to the present invention contains, as a water soluble polymer compound, carboxymethyl cellulose and/or polyvinyl pyrrolidone. The added amount of carboxymethyl cellulose in the medium is preferably 0.001 µg/mL to 1 mg/mL in terms of the final concentration. Further, the added amount of polyvinyl pyrrolidone in the medium is preferably 0.05 µg/mL to 2 mg/mL in terms of the final concentration.
C12N 1/00 - Micro-organismes, p. ex. protozoairesCompositions les contenantProcédés de culture ou de conservation de micro-organismes, ou de compositions les contenantProcédés de préparation ou d'isolement d'une composition contenant un micro-organismeLeurs milieux de culture
The present invention provides: a stabilizer for stem cell chromosomes, said stabilizer being characterized by comprising, as an active ingredient, β-nicotinamide mononucleotide, a pharmacologically acceptable salt thereof or a solvate of the same; and a method for culturing stem cells, said method being characterized by comprising culturing pluripotent stem cells in a culture medium containing β-nicotinamide mononucleotide, a pharmacologically acceptable salt thereof or a solvate of the same.
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
17.
COMPOUND COMPRISING β-NICOTINAMIDE MONONUCLEOTIDE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF, AND METHOD FOR EVALUATING QUALITY AND METHOD FOR ASSESSING ENZYMATIC REACTIVITY OF SAID COMPOUND
A compound comprising β-nicotinamide mononucleotide or a pharmacologically acceptable salt thereof, wherein the purity measured by HPLC is 95% or higher, and the reactivity to lactate dehydrogenase is 30 U or higher.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
18.
METHOD FOR KEEPING QUALITIES OF COOKED RICE AND METHOD FOR PRODUCING COOKED RICE
A method for keeping the qualities of cooked rice and a method for producing cooked rice, each method comprising a step for contacting rice with a liquid containing a polyvalent cation at any time from before cooking or steaming the rice to thereafter and a step for contacting the polyvalent cation-containing rice, which has been cooked or steamed, with a liquid containing an alginic acid salt.
A method for keeping the qualities of cooked rice and a method for producing cooked rice, each method comprising a step for contacting rice with a liquid containing a polyvalent cation at any time from before cooking or steaming the rice to thereafter and a step for contacting the polyvalent cation-containing rice, which has been cooked or steamed, with a liquid containing an alginic acid salt.
A23L 29/256 - Aliments ou produits alimentaires contenant des additifsLeur préparation ou leur traitement contenant des agents gélifiants ou épaississants d'origine végétale à base d'algues, p. ex. alginates, agar-agar ou carraghénane
The object of the present invention is to provide a material for efficiently obtaining differentiated cells from pluripotent stem cells. That is, the present invention relates to a pluripotent stem cell differentiation-promoting agent containing, as an active ingredient, a β-nicotinamide mononucleotide or a pharmacologically acceptable salt thereof, and a solvate thereof, and a method for differentiating pluripotent stem cells, including culturing pluripotent stern cells in a culture medium containing a β-nicotinamide mononucleotide or a pharmacologically acceptable salt thereof, and a solvate thereof.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
(1) Chemical additives for use in the manufacture of food, namely, quality improver for rice; Chemical additives for use in the manufacture of food, namely, quality improving agent; Food preserving chemicals, namely, shelf life improver
An object of the present invention is to provide a material which can be safely ingested and which inhibits skin pigmentation. Therefore, the invention is a skin pigmentation inhibitor, containing a β-nicotinamide mononucleotide or a pharmaceutically acceptable salt thereof; and a solvate thereof as an active ingredient; a health supplement which contains the skin pigmentation inhibitor and is ingested to inhibit skin pigmentation; and a method for inhibiting skin pigmentation, including ingesting the skin pigmentation inhibitor.
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
An object of the present invention is to provide a material capable of further accelerating growth of pluripotent stem cells, such as pluripotent stem cells, without impairing pluripotency thereof. In other words, the invention is an agent for accelerating growth of pluripotent stem cells, containing a β-nicotinamide mononucleotide or a pharmaceutically acceptable salt thereof, and a solvate thereof as an active ingredient; and is a method for culturing pluripotent stem cells, including culturing pluripotent stem cells in a culture medium that contains a β-nicotinamide mononucleotide or a pharmaceutically acceptable salt thereof, and a solvate thereof.
The present invention addresses the problem of providing a material for efficiently obtaining differentiated cells from pluripotent stem cells. Specifically, the present invention provides: a differentiation promoter for pluripotent stem cells that is characterized by having, as an active ingredient, β-nicotinamide mononucleotide, a pharmacologically acceptable salt thereof, or a solvate of either; and a method for causing pluripotent stem cells to differentiate that is characterized in that pluripotent stem cells are cultivated in a culture medium containing β-nicotinamide mononucleotide, a pharmacologically acceptable salt thereof, or a solvate of either.
C12N 1/38 - Stimulation chimique de la croissance ou de l'activité par addition de composés chimiques qui ne sont pas des facteurs essentiels de croissanceStimulation de la croissance par élimination d'un composé chimique
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
Provided is an osteogenesis promoter for promoting the differentiation of osteoblast precursor cells into osteoblast cells, and the calcification of the osteoblast cells. The osteogenesis promoter includes, as an active ingredient, a substance which bonds to a TNF-related apoptosis-inducing ligand (TRAIL) receptor, said substance being a TRAIL or anti-TRAIL receptor antibody.
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61P 3/14 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase des électrolytes de l'homéostase du calcium
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 19/08 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget
A61P 19/10 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget de l'ostéoporose
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07K 14/51 - Facteur morphogénique osseuxOstéogénineFacteur ostéogéniqueFacteur inducteur d'os
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
The present invention addresses the problem of providing a material that can be safely ingested and suppresses skin pigmentation. In other words, the present invention provides: a skin pigmentation inhibitor characterized in that a β-nicotinamide mononucleotide or a pharmaceutically acceptable salt thereof, or a solvate of these substances serves as an active ingredient thereof; a health supplement that contains said skin pigmentation inhibitor and is ingested in order to suppress skin pigmentation; and a method for suppressing skin pigmentation, said method including ingesting said skin pigmentation inhibitor.
A61K 31/706 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle
The present invention addresses the problem of providing a material for further accelerating the growth of stem cells with differentiation potential, such as pluripotent stem cells, without impairing the differentiation potential thereof. That is, the present invention pertains to: an agent for accelerating the growth of stem cells with differentiation potential, characterized by containing, as active ingredients, β-nicotinamide mononucleotide (β-NMN) or a pharmaceutically acceptable salt thereof, and a solvate thereof; and a differentiation potential-having stem cells culturing method, characterized by culturing stem cells with differentiation potential in a culture medium containing β-nicotinamide mononucleotide (β-NMN) or a pharmaceutically acceptable salt thereof, and a solvate thereof.
The present invention is a method for producing citrus fruit flesh comprising: a step for (a) heat treatment and/or (b) organic acid treatment of the fruit of a citrus fruit that has at least an albedo and segment membranes; a step for separating the fruit into multiple or single sections; and a step for bringing the fruit into contact with at least one kind of enzyme selected from a group consisting of cellulase enzymes, pectinase enzymes and hemicellulase enzymes.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
30 - Aliments de base, thé, café, pâtisseries et confiseries
Produits et services
Chemicals; chemicals for use in food industry; conditioning
agents for food; chemical agents for improving the quality
of bread and cake; conditioning agents for confectionery and
bread; chemical agents for improving shelf life of
foodstuffs; chemical agents for improving quality of
foodstuffs; bacteriostats for the food industry; lye water,
lye powder(Kansui, food additive for Chinese noodles);
chemical agents for softening pounded rice cakes; enzymes;
lactic acid bacteria for use in food manufacture. Yeast; fresh yeast; dry yeast; flour paste (confectionery
and bakery creams made of wheat flour and starch as main
ingredients); flour paste in powder form; custard powder;
fermented flavor liquid; pre-ferment; sourdough powder;
baking powder; chemical leaveners; mayonnaise; salad
dressings; ketchup [sauce]; pizza sauce; yeast extract; malt
extract for food; brown rice (prepared); sprouted rice
(prepared); roasted rye.
The purpose of the present invention is to improve the storage stability, heat resistance and long-term stability of a flour paste and to reduce the cost required for the transportation, storage and production of a flour paste. The present invention provides a powder composition for preparing a flour paste, said powder composition comprising predetermined amounts of a modified starch, an unmodified starch, a milk whey protein and a thickening agent.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
30 - Aliments de base, thé, café, pâtisseries et confiseries
31 - Produits agricoles; animaux vivants
Produits et services
Chemicals for use in food and beverages industry;
conditioning agents for food; chemical agents for
conditioning quality of foodstuffs; chemical agents for
improving shelf life of foodstuffs; chemical agents for
improving quality of foodstuffs; bacteriostats for use in
industry; lye water (Kansui, food additive for Chinese
noodles); chemical agents for softening foodstuffs;
biochemistry reagent kit including chemical substances and
biochemical other than for medical and veterinary use;
enzymes; medium for microorganisms or medium for cell
cultures other than for medical and veterinary use; stem
cells other than for medical or veterinary purpose; protein;
other chemicals. Confectionery and bakery creams made of wheat flour and
starch as main ingredients; flour paste in powder form
(confectionery and bakery creams made of wheat flour and
starch as main ingredients); flour paste (confectionery and
bakery creams made of wheat flour and starch as main
ingredients); confectionery; bread and buns; sandwiches;
Chinese buns; hamburger sandwiches; pizzas; hot dogs
[sandwiches]; meat pies; pizza sauce; powdered mayonnaise
mixes; other seasonings [other than spices]; brown rice
(prepared); sprouted rice (prepared); processed grains;
Chinese stuffed dumplings; Chinese steamed dumplings; sushi;
fried balls of batter mix with small pieces of octopus
[Takoyaki]; boxed lunches consisting of rice, with added
meat, fish or vegetables; ravioli; yeast extract;
pre-ferment; yeast powder; koji [fermented malted rice];
yeast; baking powder; malt extract for food; custard powder;
instant confectionery mixes; fermented flavor liquid; food
flavorings other than food flavorings prepared from
essential oils; roasted rye; rice; husked oats; husked
barley; flour mixes; flour. Foodstuffs for animals; live animals; laboratory animals.
32.
BAKING POWDER, METHOD FOR MANUFACTURING SAME, AND FOOD USING BAKING POWDER
The purpose of the present invention is to provide a baking powder having excellent delayed effectiveness. Provided is a baking powder comprising sodium bicarbonate and acidic agents, said acidic agents having a median diameter of 100 μm or more and being coated with a fat having a melting point of 55-75oC, wherein: the acidic agents consist of one or more kinds of acidic agents having a median diameter of 100 μm or more and one or more kinds of acidic agents having a median diameter of less than 100 μm; and one or more kinds of acidic agents having a median diameter of 100 μm or more are surface-coated with the fat containing one or more kinds of acidic agents having a median diameter of less than 100 μm.
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
NISSHIN SEIFUN GROUP INC. (Japon)
ORIENTAL YEAST CO.,LTD. (Japon)
Inventeur(s)
Oishi, Katsutaka
Itoh, Nanako
Yamamoto, Saori
Fukudome, Shin-Ichi
Kikuchi, Yosuke
Okita, Kimiko
Abrégé
An agent for improving glucose tolerance disorder that comprises, as an active ingredient, partition chromatography peak components of an alcoholic extract of gramineous plant seeds, said peak components preferably comprising an alkyl resorcinol (AR) mixture containing multiple kinds of alkyl resorcinols. This mixture preferably contains an AR of general formula (I) wherein R1 is a saturated or unsaturated alkyl group having 15 carbon atoms, an AR of general formula (I) wherein R1 is a saturated or unsaturated alkyl group having 17 carbon atoms, an AR of general formula (I) wherein R1 is a saturated or unsaturated alkyl group having 19 carbon atoms, an AR of general formula (I) wherein R1 is a saturated or unsaturated alkyl group having 21 carbon atoms, an AR of general formula (I) wherein R1 is a saturated or unsaturated alkyl group having 23 carbon atoms, and an AR of general formula (I) wherein R1 is a saturated or unsaturated alkyl group having 25 carbon atoms, each in a specific amount. In general formula (I): R1 represents a saturated or unsaturated alkyl group having 15-25 carbon atoms; and R2 represents a hydrogen atom or a methyl group.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Chemicals; chemicals for use in food industry; chemical
agents for improving shelf life of foodstuffs; chemical
agents for improving quality of foodstuffs.
35.
Method of regulating circadian rhythm, and method of preparing circadian rhythm regulatory agent
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Chemicals for use in industry; chemicals for use in food industry; chemical agents for improving shelf life of foodstuffs; chemical agents for improving quality of foodstuffs
The purpose of the present invention is to provide: a formate dehydrogenase having a high specific activity; and a method for producing a formate dehydrogenase with high efficiency without using methanol. The present invention relates to: a novel formate dehydrogenase; a gene encoding the formate dehydrogenase; a method for producing the formate dehydrogenase; and a method for regenerating a coenzyme using the formate dehydrogenase.
C12N 1/15 - ChampignonsLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/19 - LevuresLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
C12N 9/04 - Oxydoréductases (1.), p. ex. luciférase agissant sur des groupes CHOH comme donneurs, p. ex. oxydase de glucose, déshydrogénase lactique (1.1)
Provided is a method for manufacturing a yeast extract containing copper includes an extraction step wherein yeast containing copper is suspended in a solution that contains an amino acid or a salt thereof and the solid components and liquid components of the suspension obtained are separated with the amino acid or salt thereof being water-soluble. Also provided are a yeast extract containing copper, a food product, and a green color preserving and restoring agent for vegetables.
Problem: To provide a preparation capable of easily and efficiently improving the quality of filling-containing breads, in particular, filling-containing breads in which the amount of filling is comparatively large and/or the water content in the filling is high, and a production method, and the like, for breads using the preparation. Solution: By adding and mixing an alginate ester, powdered egg yolk, and modified starch in bread dough for filling-containing breads, the migration of moisture from the filling to the bread part is suppressed and sogginess of the bread in such breads is suppressed even if there is a migration of moisture, peeling of the bread crust is suppressed, sticking of the bread is suppressed, and the bread is imparted with a flaky texture, as a result of which the bread quality can be improved.
Problem: To provide a bread quality improving agent suitable for frozen dough with which it is possible to prepare breads from frozen bread dough without a decrease in the quality (for example, the bread volume, bread height, specific volume, crust quality, etc.) of the breads, and a production method, and the like, for breads using the improving agent. Solution: A bread quality improving agent for frozen dough is used which includes transglutaminase, L-ascorbic acid, and a bread emulsifier. In addition, bread dough is prepared combined with the bread quality improving agent for frozen dough, the bread dough is frozen following any of the steps of primary fermentation, shaping, and final fermentation, and breads are produced therefrom according to conventional methods.
A method for producing a high-zinc-content yeast extract, including extracting the high-zinc-content yeast extract by suspending zinc-containing yeast into a solution containing a carboxylic acid, a carboxylic acid salt, or both thereof to thereby obtain a suspension liquid, and separating a solid component and a liquid component of the suspension liquid; the high-zinc-content yeast extract; food; and an agent for maintaining and restoring a green color of vegetables.
A23L 1/28 - Extraits ou préparations comestibles de champignons (à usage médicinal A61K)
A23L 1/272 - Maintien ou altération de la coloration naturelle par l'emploi d'additifs, p.ex. d'adjuvants optiques (A23L 1/275 a priorité);;
A61K 36/064 - Saccharomycetales, p. ex. levure de boulanger
A23L 1/30 - contenant des additifs (A23L 1/308 a priorité);;
A23L 1/304 - Sels inorganiques, minéraux, oligo-éléments
A23L 1/212 - Préparation des fruits ou des légumes (des légumineuses A23L 1/20; traitement par grandes quantités des fruits ou des légumes récoltés A23N)
A23L 3/3508 - Composés organiques contenant de l'oxygène contenant des groupes carboxyle
Provided are: a method that is for producing a high-iron-content yeast extract and that contains an extraction step for suspending iron-containing yeast in a solution containing a carboxylic acid and/or a carboxylate, and separating the solid component and liquid component of the obtained suspension; a high-iron-content yeast extract; and a food product.
[Problem] To provide: a novel quality-preserving agent which can preserve the quality of a peeled and/or cut vegetable or fruit or a seafood during storage in a simple manner and effectively and is highly safe; and others. [Solution] The quality-preserving agent contains two components, i.e., sodium acetate and α-lipoic acid, as active ingredients. The quality-preserving agent can prevent the discoloration, brownish discoloration or the like of a peeled and/or cut vegetable or fruit or a seafood during chilled storage and ambient-temperature storage of the vegetable or fruit or the seafood, can improve the shelf life of the vegetable or fruit or the seafood, and can preserve the quality of the vegetable or fruit or the seafood in a simple manner and effectively merely by bringing the vegetable or fruit or the seafood into contact with the quality-preserving agent.
A method for producing a manganese-rich yeast extract, which involves an extraction step of suspending manganese-containing yeast in a solution containing a carboxylic acid and/or a carboxylic acid salt and then separating the resultant suspension into a solid component and a liquid component; a manganese-rich yeast extract; a food; a composition for a culture medium for an edible lactic acid bacterium; a culture medium for an edible lactic acid bacterium; and a method for culturing an edible lactic acid bacterium.
[Problem] To provide a highly safe preparation, method and the like whereby the qualities of at least one product selected from among breads, confectioneries, doughnuts, pies and Chinese dumpling skins can be easily and effectively improved. [Solution] A quality improving agent which comprises, as active ingredients, glycine and a pentose and/or a hexose. By kneading the quality improving agent into a dough, at least one quality improving effect can be exerted on at least one product selected from among breads, confectioneries, doughnuts, pies and Chinese dumpling skins, said quality improving effect being selected from, in particular: imparting a baked and/or fried brown color and promoting browning; shortening the baking and/or frying time; lowering the baking and/or frying temperature; reducing moisture loss in the baking and/or frying step and improving the texture; preventing skin-peeling and cracking in baked frozen breads or parbaked frozen products; and thinning the crust film of baked breads and thus improving the texture and increasing the crumb ratio.
A method for producing a yeast extract with a high copper content, said method being characterized by compirising an extraction step for suspending a copper-containing yeast in a solution containing a carboxylic acid and/or a carboxylic acid salt and then separating the solid component of the obtained suspension from the liquid component; a yeast extract with a high copper content; and an agent for maintaining and restoring the green color of foods and vegetables.
[Problem] To provide a novel quality-keeping agent with a high safety whereby the qualities of peeled and/or cut vegetables, fruits and so on can be easily and effectively maintained during storage. [Solution] During cold or room-temperature storage of peeled and/or cut vegetables or fruits, color change, browning and so on can be prevented and the qualities can be easily and effectively maintained simply by using, as the active components, three components (i.e., sodium citrate, alum and α-lipoic acid) or four components (i.e., sodium citrate, alum, α-lipoic acid and sodium tartrate) and contacting the peeled and/or cut vegetables or fruits therewith.
Provided is a method for producing a liquid fermented milk having favorable flavor and appearance, having no occurrence of solid content floating up, having no contained large particles observed with the naked eye after completion of stirring fermentation, and having a rich aroma and the like deriving from fermentation by yeast. The method for producing a liquid fermented milk contains: (A) a static fermentation step that, after adding a lactobacillus to the starting material for fermented milk, causes static fermentation to obtain a lactic acid fermentation product; (B) a stirring fermentation step that, after adding yeast to the lactic acid fermentation product obtained in step (A), causes stirring fermentation to obtain a liquid fermented milk; and (C) a homogenization step for subjecting the liquid fermented milk obtained in step (B) to homogenization processing.
A23C 9/127 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes comportant des micro-organismes de la famille des lactobactériacées et d'autres micro-organismes ou des enzymes, p. ex. kéfir, koumiss
A23C 9/13 - Préparations à base de lait fermentéTraitements utilisant des micro-organismes ou des enzymes comportant l'emploi d'additifs
51.
METHOD FOR PRODUCING ZINC-RICH YEAST EXTRACT, ZINC-RICH YEAST EXTRACT, AND GREEN-RETAINING/-RESTORING AGENT FOR FOOD AND VEGETABLES
A method for producing a high-zinc-content yeast extract, including extracting the high-zinc-content yeast extract by suspending zinc-containing yeast into a solution containing a carboxylic acid, a carboxylic acid salt, or both thereof to thereby obtain a suspension liquid, and separating a solid component and a liquid component of the suspension liquid; the high-zinc-content yeast extract; food; and an agent for maintaining and restoring a green color of vegetables.
A method for producing a zinc-rich yeast extract, the method comprising an extraction step for suspending a yeast containing zinc in a solution including carboxylic acid and/or carboxylic acid salt, and separating the solid component and liquid component of the resulting suspension; a zinc-rich yeast extract; and a green-retaining/-restoring agent for food and vegetables.
A23L 1/28 - Extraits ou préparations comestibles de champignons (à usage médicinal A61K)
A23L 1/212 - Préparation des fruits ou des légumes (des légumineuses A23L 1/20; traitement par grandes quantités des fruits ou des légumes récoltés A23N)
A23L 1/272 - Maintien ou altération de la coloration naturelle par l'emploi d'additifs, p.ex. d'adjuvants optiques (A23L 1/275 a priorité);;
53.
METHOD FOR CULTURING MAMMALIAN CELL IN SYSTEM CONTAINING LAMININ 511
The purpose of the present invention is to provide a method for culturing a mammalian cell in a system containing laminin 511. The method according to the present invention is characterized by culturing the cell under such conditions that a blood protein other than an extracellular matrix protein, which is serum, serum albumin, prealbumin, an immunoglobulin, α-globulin, β-globulin, α1-antitrypsin (α1-AT), haptoglobin (Hp), α2-macroglobulin (α2-M), α-fetoprotein (AFP), transferrin, a retinol-binding protein (RBP) or adiponectin, a polypeptide and/or a peptide selected from the group consisting of gelatin, a protein belonging to a tumor necrosis factor (TNF) family and peptone, and laminin 511 are solid-phased.
The objective of the present invention is to provide: a method for producing frozen whipping cream wherein the cream can be refrigerated, the creaminess of the cream after thawing is the same as refrigerated cream, and quality in terms of smoothness and melting in the mouth when made into whipped cream is the same as whipped cream made by whipping refrigerated cream; frozen whipping cream produced by the method; and whipped cream using the frozen whipping cream and a method for making the same. The present invention is: a method for producing frozen whipping cream which includes a cooling step for cooling fresh cream, the fresh cream being passed from 0°C to -5°C in 8 minutes or less in the cooling step; frozen whipping cream produced by the method; whipped cream using the frozen whipping cream; and a method for making the same.
A method for producing frozen fresh cream to be whipped, the method including: cooling fresh cream, wherein in the cooling, the fresh cream is cooled to a temperature of −5° C. or lower and is changed from 0° C. to −5° C. for 8 minutes or shorter.
The invention provides a potentiator of cancer immunity containing a compound which blocks the action of RANKL. The invention is a potentiator of cancer immunity containing, as an active ingredient, a RANKL antagonist such as an anti-RANKL neutralizing antibody.
The invention provides a potentiator of cancer immunity containing a compound which blocks the action of RANKL. The invention is a potentiator of cancer immunity containing, as an active ingredient, a RANKL antagonist such as an anti-RANKL neutralizing antibody.
Disclosed is a method which improves the quality of at least one item chosen from bread, noodles and sweets, and which imparts a softness and moistness and makes the item not prone to aging even after a certain period has elapsed after manufacture (aging is suppressed and prevented); also disclosed is an agent used in said method. Softness and moistness can be imparted to at least one item chosen from bread, noodles and sweets, and aging can be suppressed and prevented during storage after manufacture by adding to wheat flour and/or rice flour, which is the main ingredient, four components: α-amylase, β-amylase and a partial α-starch, and a processed product of seaweed belonging to the genus Lessonia of the order Laminariales.
Disclosed is a method for culturing cells in a system containing laminin-5. This method is characterized by including a culture system for polypeptides selected from a group consisting of serum, serum albumin, prealbumin, immunoglobulin, alpha globulins, beta globulins, α1-antitrypsin (α1-AT), haptoglobin (Hp), α2-macroglobulin (α2M), α-fetoprotein (AFP), transferrin, retinol binding protein (RBP), and proteins in the blood other than extracellular matrix proteins as well as gelatin, proteins belonging to the tumor necrosis factor (TNF) family and peptones.
C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]
C07K 14/79 - Transferrines, p. ex. lactoferrines, ovotransferrines
60.
Fusion protein composed of matrix metalloproteinase-2 inhibitor peptide derived from amyloid-B precursor protein and tissue inhibitor of metalloproteinase-2
The present invention provides an agent capable of inhibiting MMP-2 specifically. Disclosed is a fusion molecule composed of a β-amyloid precursor protein molecule-derived domain having an activity of selectively inhibiting matrix metalloproteinase-2 and a tissue inhibitor of metalloproteinase capable of binding to latent matrix metalloproteinase. Also disclosed are a pharmaceutical composition, a cancer metastasis and/or angiogenesis inhibitor, a therapeutic and/or prophylactic for cardiovascular diseases, and a matrix metalloproteinase-2 inhibitor, each of which comprises the fusion molecule.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
61.
Inducer of chondrocyte proliferation and differentiation
This invention provides a method for administration of an effective amount of RANKL-binding molecules that act on prechondrocytes and/or mesenchymal stem cells, accelerate cartilage differentiation, proliferation, and maturation of such cells, enhance chondrocyte differentiation, and induce chondrocyte proliferation to induce chondrocyte proliferation and differentiation or increase cartilage matrix production and a pharmaceutical composition used for inducing chondrocyte proliferation and differentiation or increasing cartilage matrix production. The pharmaceutical composition used for treatment or prevention of a chondropathies comprises, as an active ingredient, a compound that acts on prechondrocytes and/or mesenchymal stem cells and induces at least one of the following: (a) acceleration of prechondrocyte and/or mesenchymal stem cell differentiation; (b) acceleration of prechondrocyte and/or mesenchymal stem cell proliferation; (c) acceleration of prechondrocyte and/or mesenchymal stem cell maturation; (d) enhancement of chondrocyte differentiation; (e) chondrocyte proliferation; and (f) increased production of the cartilage matrix.
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
Provided is a technique for observing in real time the state of a disease condition in a tissue of an animal or the state of a functionally adverse condition which is a prelude to the disease condition without injuring the animal. This can be achieved by the use of a gene construct having a reporter gene integrated under the control of a hypoxia responsible promoter an ODD domain (oxygen dependent degradation domain) integrated upstream to the reporter gene.
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
(1) Chemical additives for use in the manufacture of food; KANSUI, namely, food additive for making Chinese noodle; biochemical reagents, namely, diagnostic reagents for clinical laboratory use; enzymes for food manufacturing; enzymes for the bakery industry as ingredients used in the manufacture of biochemistry reagents.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
29 - Viande, produits laitiers et aliments préparés ou conservés
30 - Aliments de base, thé, café, pâtisseries et confiseries
Produits et services
Quality improving agents for confectionery and bakery; dough conditioners; dough stabilizers; kansui (food additive for manufacture of Chinese noodle); ingredients for use in the manufacture of foods; preservatives for foodstuffs; bacteriostatic agents for foodstuffs; diagnostic reagents and preparations, except for medical or veterinary use; reagents for scientific purposes; immunochemistry reagents; biochemistry reagents; enzymes [other than for medical or veterinary use]; culture media for microbiology; flavour enhancers for foodstuffs; chemical products for the preparation of flavourings; softening preparations for pounded rice cakes (mochi) (chemical preparations). Dietary food supplements; powdered and granulated processed dietary food supplements made of yeast; biological and chemical preparations and reagents for medical or veterinary use; enzymes for medical or veterinary use. Buttercream; curry [prepared meals with or without rice]; prepared sweet or fruit fillings. Yeast; yeast extracts; confectionery made mainly of wheat flour and starches; confectionery and bakery creams (paste) made mainly from wheat flour and starches; custard powder; curry powder; curry paste; curry sauces; bakery products; mixes for making bakery products; pre-ferment; baking powder; mayonnaise; powdered mayonnaise; dressings for food; rice; brown rice (prepared); sprouted rice; roasted rye; flavourings and essences for food and beverages; fermented liquid flavouring; dough; dough mix; softening preparations for pounded rice cakes (mochi) (other than chemical preparations).
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Chemicals for industrial purposes; chemical additives for use in the manufacture of food; Kansui, namely, chemical additives for use in the manufacture of food; [ bacteriostatic agents for use in the manufacture of food; ] Biochemical reagents used for non-medical purposes; [ Enzymes for use in the food industry; ]enzymes as ingredients used in manufacture of biochemistry reagents; [ Bacteria for use in food manufacture ]
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
(1) Chemical additives for use in the manufacture of food; KANSUI, namely, food additive for making Chinese noodle; biochemical reagents, namely, diagnostic reagents for clinical laboratory use; enzymes for food manufacturing; enzymes for the bakery industry as ingredients used in the manufacture of biochemistry reagents.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
29 - Viande, produits laitiers et aliments préparés ou conservés
30 - Aliments de base, thé, café, pâtisseries et confiseries
Produits et services
Quality improving agents for confectionery and bakery; dough conditioners; dough stabilizers; kansui (food additive for manufacture of Chinese noodle); ingredients for use in the manufacture of foods; preservatives for foodstuffs; bacteriostatic agents for foodstuffs; diagnostic reagents and preparations, except for medical or veterinary use; reagents for scientific purposes; immunochemistry reagents; biochemistry reagents; enzymes [other than for medical or veterinary use]; culture media for microbiology; flavour enhancers for foodstuffs; chemical products for the preparation of flavourings; softening preparations for pounded rice cakes (mochi) (chemical preparations). Dietary food supplements; powdered and granulated processed dietary food supplements made of yeast; biological and chemical preparations and reagents for medical or veterinary use; enzymes for medical or veterinary use. Buttercream; curry [prepared meals with or without rice]; prepared sweet or fruit fillings. Yeast; yeast extracts; confectionery made mainly of wheat flour and starches; confectionery and bakery creams (paste) made mainly from wheat flour and starches; custard powder; curry powder; curry paste; curry sauces; bakery products; mixes for making bakery products; pre-ferment; baking powder; mayonnaise; powdered mayonnaise; dressings for food; rice; brown rice (prepared); sprouted rice; roasted rye; flavourings and essences for food and beverages; fermented liquid flavouring; dough; dough mix; softening preparations for pounded rice cakes (mochi) (other than chemical preparations).
69.
Method of separating and distinguishing walnut from pecan nut
Provided is a method whereby walnut can be simply, rapidly and accurately separated and distinguished from pecan nut. The method involves a PCR method for specifically detecting nuts of the family Juglandaceae and identifying the matK sequence of pecan nut to thereby discriminate walnut and pecan nut from each other optionally using restriction enzymes.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
70.
Polypeptide for unstabilizing protein in cells under aerobic conditions and DNA encoding the same
To identify a domain in HIF-1α protein, which participates in stabilization of a fused protein, DNA encoding the following polypeptide (A) or (B) is provided:
(A) a polypeptide having the amino acid sequence of SEQ ID NO: 1
(B) a polypeptide having an amino acid sequence comprising at least 16 amino acid residues in the amino acid sequence of SEQ ID NO: 1, and imparting stability dependent on an oxygen concentration to other protein in a cell harboring a fused protein, when the polypeptide is fused with a nuclear localization signal and the other protein to form the fused protein.
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le ribosyle comme radical saccharide
C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
71.
FUSION PROTEIN COMPOSED OF MATRIX METALLOPROTEINASE-2 INHIBITOR PEPTIDE DERIVED FROM AMYLOID-Β PRECURSOR PROTEIN AND TISSUE INHIBITOR OF METALLOPROTEINASE-2
Disclosed is a substance capable of inhibiting MMP-2 specifically. Specifically disclosed is a fusion molecule composed of: a region which has an activity to selectively inhibit matrix metalloproteinase-2 and is contained in an amyloid-β precursor protein molecule; and a tissue inhibitor of metalloproteinase which can bind to a latent matrix metalloproteinase. Also disclosed are a pharmaceutical composition, a cancer metastasis and/or angiogenesis inhibitor, a therapeutic and/or prophylactic agent for cardiovascular diseases, and a matrix metalloproteinase-2 inhibitor, each of which comprises the fusion molecule.
A61K 38/00 - Préparations médicinales contenant des peptides
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 9/04 - Agents inotropes, c.-à-d. stimulants de la contraction cardiaqueMédicaments pour le traitement de l'insuffisance cardiaque
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
The present invention provides a method for producing an osteopenia animal model by RANKL administration and an osteopenia animal model.
Also, a method for producing an osteopenia animal model, comprising administering soluble RANKL or a fused protein of soluble RANKL with an epitope tag to a non-human animal so as to promote vivo osteoclast differentiation and activation in the non-human animal, and an osteopenia animal model produced by the method are provided.
Disclosed is a method for inducing the proliferation/differentiation of a cartilage cell or increasing the production of a cartilage substrate by administering an effective amount of a RANKL-binding molecule which can act on a cartilage progenitor cell and/or a mesenchymal stem cell to promote the differentiation of the cartilage progenitor cell and/or the mesenchymal stem cell into a cartilage or the proliferation or maturation of the cartilage progenitor cell and/or the mesenchymal stem cell, enhance the differentiation of a cartilage cell and induce the proliferation of a cartilage cell. Also disclosed is a pharmaceutical composition for inducing the proliferation/differentiation of a cartilage cell or increasing the production of a cartilage substrate. Specifically disclosed is a pharmaceutical composition for treating or preventing a cartilage disease, which comprising a compound capable of acting on a cartilage progenitor cell and/or a mesenchymal stem cell to induce at least one phenomenon selected from the following items (a) to (f) as an active ingredient: (a) the promotion of the differentiation of the cartilage progenitor cell and/or the mesenchymal stem cell; (b) the promotion of the proliferation of the cartilage progenitor cell and/or the mesenchymal stem cell; (c) the promotion of the maturation of the cartilage progenitor cell and/or the mesenchymal stem cell; (d) the enhancement of the cartilage cell differentiation; (e) the proliferation of a cartilage cell; and (f) the increase in the production of a cartilage substrate.
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 38/00 - Préparations médicinales contenant des peptides
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 19/08 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
74.
STANDARD MOLECULE FOR USE IN REAL-TIME PCR TEST, AND DETECTION OF THE STANDARD MOLECULE
Disclosed are: a standard molecule characterized in that the presence of a false-positive result caused by unintended contamination of a reagent, a sample or the like with the standard molecule can be confirmed simultaneously with the determination of the test results in real-time PCR test; a primer; a probe; and a test method using the standard molecule, the primer and the probe. In a real-time PCR test, the presence of a false-positive result caused by contamination with a standard molecule for a real-time PCR test can be determined simultaneously by carrying out the test using the standard molecule and a primer/probe, wherein the standard molecule contains both an artificial DNA sequence and a target region of DNA to be tested, wherein the artificial DNA sequence can be amplified under the same PCR conditions and in the same reaction vessel as those for the target region of the DNA to be tested in the real-time PCR test, and wherein the primer/probe is one used for amplifying/detecting only the DNA sequence.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
To newly develop a system for imparting heat resistance to a food antioxidant (in particular, a food antioxidant containing β-amylase as the active ingredient). To solve the above-described problem, a material for imparting heat resistance to a food antioxidant containing β-amylase as the active ingredient that is characterized by being at least one member selected from among a yeast-treated material, a yam powder and a modified cellulose and capable of imparting heat resistance of 90°C or higher has been developed.
A21D 13/00 - Produits de boulangerie complètement ou partiellement finis
A21D 13/08 - Pâtisseries, p.ex. gâteaux, biscuits, feuilletés (glaçage ou givrage ou mélanges pour les réaliser A23G 3/00)
A23G 3/34 - Sucreries, confiseries ou massepainProcédés pour leur fabrication
A23G 3/48 - Sucreries, confiseries ou massepainProcédés pour leur fabrication caractérisés par la composition contenant des végétaux ou des parties de ceux-ci, p. ex. des fruits, des graines, des extraits
A23L 1/10 - contenant des produits dérivés des céréales
A23L 1/48 - Compositions d'aliments ou leur traitement non prévus par les sous-groupes précédents
C12N 9/96 - Stabilisation d'une enzyme par formation d'un adduct ou d'une compositionFormation de conjugaisons d'enzymes
76.
POLYNUCLEOTIDE FOR RELEASING RECOMBINANT PROTEIN TO THE OUTSIDE OF EUKARYOTIC CELL
Disclosed is a method for producing a recombinant protein efficiently by expressing the recombinant protein in a eukaryotic cell host and releasing the recombinant protein to the outside of the cell. Specifically disclosed is a polynucleotide which can be used for producing a recombinant protein in a host cell. The polynucleotide comprises: a polynucleotide encoding an endoplasmic reticulum-insertion signal sequence and a glycosylated sequence comprising a sequence represented by the formula: Asn-X-(Thr/Ser) [wherein X represents an amino acid residue other than proline]; and a polynucleotide encoding a protein of interest that cannot be released efficiently to the outside of a host even when the protein is fused with an endoplasmic reticulum-insertion signal sequence. The polynucleotide enables the release of the protein of interest to the outside of the hose cell in a glycosylation-dependent manner.
Disclosed is an agent for improving at least one activity selected from the group consisting of the growth activity, adhesion activity and extension activity of mesenchymal stem cells, which comprises laminin-5 as an active ingredient. A method of culturing mesenchymal stem cells; a method of isolating mesenchymal stem cells; and a medium, vessel or sheet for use in culturing mesenchymal stem cells are also provided.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12N 5/02 - Propagation de cellules individuelles ou de cellules en suspensionLeur conservationMilieux de culture à cet effet
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
The object aims to proliferate a pluripotent stem cell efficiently in a system which does not use any animal-derived material such as a feeder cell or a serum. Thus, disclosed is a method for proliferating a pluripotent stem cell, which comprises culturing the pluripotent stem cell in a culture medium containing no feeder cell or serum in a system containing laminin-5.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
The object aims to proliferate a pluripotent stem cell efficiently in a system which does not use any animal-derived material such as a feeder cell or a serum. Thus, disclosed is a method for proliferating a pluripotent stem cell, which comprises culturing the pluripotent stem cell in a culture medium containing no feeder cell or serum in a system containing laminin-5.
A novel method for detection of an inflammatory disease and a novel composition for prevention or treatment of an inflammatory disease are provided. The method for detection of an inflammatory disease comprises using RANKL and/or OPG as a marker in a biological sample. The composition for prevention or treatment of an inflammatory disease comprises RANKL and/or M-CSF as an active ingredient.
This object aims to provide a yeast which has a high safety, can exerts a high immunopotentiating effect even in the case of being taken as cells, is easily available and less expensive, can be directly employed in producing foods and can be cultured even at a low osmotic pressure, and a food containing this yeast. A yeast characterized by containing only a small amount of mannan in the cell wall, having an immunopotentiating effect and being capable of growing in YPD liquid medium having an osmotic pressure of 300 m Osm. The above-described yeast is preferably either of Saccharomyces cerevisiae FERM AP-21354 or Saccharomyces cerevisiae FERM AP-21355.
Disclosed is a bone formation enhancing agent comprising an RANKL-acting molecule which can enhance the differentiation, maturation or calcification of an osteoblast or a cell capable of being differentiated into an osteoblast. Specifically disclosed is a pharmaceutical composition for the treatment or prevention of a metabolic bone disease accompanied by the decrease in bone mass, which comprises, as an active ingredient, a compound which can act on an RANKL located on an osteoblast or a cell capable of being differentiated into an osteoblast to accelerate the differentiation, proliferation, maturation or calcification of the osteoblast or the cell capable of being differentiated into an osteoblast.
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 38/00 - Préparations médicinales contenant des peptides
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 19/08 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget
A61P 19/10 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget de l'ostéoporose
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
It is intended to provide a determination method for an allergic disease which is capable of performing a multidimensional and comprehensive analysis with a small amount of a specimen and particularly suppressing a non-specific reaction as much as possible thereby to enable an accurate measurement with high sensitivity even if a body fluid other than blood such as saliva, nasal discharge or lacrimal fluid is used as the specimen. After a chemically-modified diamond/DLC (Diamond-like Carbon) chip is activated by an activating reagent, a coupling reaction of an allergen or a peptide containing an allergen epitope is performed and a specimen (such as saliva, nasal discharge or lacrimal fluid) subjected to pressure filtration with a low protein adsorptive filter is subsequently brought into contact with an allergen determination chip subjected to a washing and blocking procedure against an unreacted active group, and an allergen recognition antibody in the specimen captured by the allergen determination chip is detected through an immunoassay using a labeled secondary antibody. At this time, as a washing liquid and/or a blocking liquid to be used in the washing and blocking procedure, a glycine-containing liquid is used.
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 21/78 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique produisant un changement de couleur
G01N 33/531 - Production de matériaux de tests immunochimiques
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
84.
METHOD OF SEPARATING AND DISTINGUISHING WALNUT FROM PECAN NUT
[PROBLEMS] To newly develop a method whereby walnut can be conveniently, quickly and accurately separated and distinguished from pecan nut. [MEANS FOR SOLVING PROBLEMS] With the recent increase in the patients with walnut allergy and an increase in pecan nut imports in Japan, it has been urgently required to develop a method of distinguished walnut from pecan nut. Paying attention to chloroplast matK gene having a clarified gene sequence, a PCR method for specifically detecting a nut belonging to the family Juglandaceae is developed. To distinguish walnut from pecan nut, furthermore, pecan nut matK sequence is clarified and thus amethod of distinguished walnut from pecan nut with the use of a restriction enzyme is established.
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
It is intended to provide a novel method of detecting mammary cancer cells with the use of a change in the expression level of a specific gene in a human mammary cancer tissue (or cells) as an indication. This object is achieved by providing a detection method characterized by comprising: (1) measuring the expression level of a gene having a specific base sequence in a human mammary cancer tissue (or cells); (2) measuring the expression level of the above-described gene in a normal human mammary gland tissue (or cells); and (3) comparing the values measured in the above (1) and (2) and thus detecting mammary cancer cell on the basis of the difference therein.
It is intended to provide a reagent containing a fused protein of RANKL with an epitope tag which has an improved effect of differentiating and activating osteoclasts compared with the case of using RANKL alone and an improved storage stability. An agent of differentiating and activating osteoclasts in vitro or in vivo which contains a fused protein of soluble RANKL with an epitope tag peptide as the active ingredient.
C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
C12N 5/078 - Cellules du sang ou du système immunitaire
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
The present invention provides a method for producing an osteopenia animal model by RANKL administration and an osteopenia animal model. Also, a method for producing an osteopenia animal model, comprising administering soluble RANKL or a fused protein of soluble RANKL with an epitope tag to a non-human animal so as to promote in vivo osteoclast differentiation and activation in the non-human animal, and an osteopenia animal model produced by the method are provided.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
It is intended to provide a method of constructing a bone loss model animal by administering RANKL and a bone loss model animal. Namely, a method of constructing a bone loss model animal which comprises administering soluble RANKL or a fused protein of soluble RANKL with an epitope tag to a nonhuman animal and thus promoting the differentiation and activation of osteoclasts in the body of the nonhuman animal; and a bone loss model animal constructed by this method.
A01K 67/027 - Nouvelles races ou races modifiées de vertébrés
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 14/475 - Facteurs de croissanceRégulateurs de croissance
Disclosed are: a method for producing an osteopenia model animal by administering RANKL; and an osteopenia model animal. Specifically disclosed are: a method for producing an osteopenia model animal, which comprises administering soluble RANKL or a fusion protein of soluble RANKL and an epitope tag to a non-human animal to stimulate the differentiation and activation of an osteoclast in the non-human animal; and an osteopenia model animal produced by the method.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
90.
REAGENT CONTAINING FUSED PROTEIN OF SOLUBLE RANKL WITH EPITOPE TAG
It is intended to provide a reagent containing a fused protein of RANKL with an epitope tag which has an improved effect of differentiating and activating osteoclasts compared with the case of using RANKL alone and an improved storage stability. An agent of differentiating and activating osteoclasts in vitro or in vivo which contains a fused protein of soluble RANKL with an epitope tag peptide as the active ingredient.
A novel method for detection of an inflammatory disease and a novel composition for prevention or treatment of an inflammatory disease are provided. The method for detection of an inflammatory disease comprises using RANKL and/or OPG as a marker in a biological sample. The composition for prevention or treatment of an inflammatory disease comprises RANKL and/or M-CSF as an active ingredient.
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions
A61K 38/00 - Préparations médicinales contenant des peptides
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Disclosed are a novel method for detecting an inflammatory disease and a novel composition for the prevention or treatment of an inflammatory disease. A method for detecting an inflammatory disease using RANKL and/or OPG in a biological sample as a marker; and a composition for the prevention or treatment of an inflammatory disease comprising RANKL and/or M-CSF as an active ingredient.
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions
A61K 38/00 - Préparations médicinales contenant des peptides
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/483 - Analyse physique de matériau biologique
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
National Institute of Radiological Sciences (Japon)
Inventeur(s)
Saito, Toshiyuki
Mikami, Yoji
Kinugasa, Masahiro
Mori, Kazuya
Sugimoto, Michiyo
Uchida, Koji
Abrégé
It is intended to provide a novel method for determining the possibility of lymph node metastasis of breast cancer using a difference of expression level of a specific gene between a human metastatic breast cancer tissue (or cell) and a nonmetastatic breast cancer tissue (or cell) as an index. For this purpose, the method characterized by: (1) measuring the expression level of a gene having a specific base sequence in a human metastatic breast cancer tissue (or cell); (2) measuring the expression level of the gene in a human nonmetastatic breast cancer tissue (or cell); and (3) comparing the measured values of (1) and (2) and determining the possibility of lymph node metastasis of breast cancer based on the difference is provided.
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
94.
TECHNIQUE FOR CULTURE OF MESENCHYMAL STEM CELL UTILIZING LAMININ-5
KIHARA MEMORIAL YOKOHAMA FOUNDATION FOR THE ADVANCEMENT OF LIFE SCIENCES (Japon)
Inventeur(s)
Miyazaki, Kaoru
Hashimoto, Junko
Kariya, Yoshinobu
Abrégé
Disclosed is a substance capable of enhancing at least one activity selected from the group consisting of growth activity, adhesion activity and extension activity of a mesenchymal stem cell. The substance comprises laminin-5 as an active ingredient. Also disclosed are a method for cultivation of a mesenchymal stem cell, a method for isolation of a mesenchymal stem cell, and a culture medium, vessel or sheet for use in the cultivation of a mesenchymal stem cell.
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
95.
SACCHAROMYCES SPECIES FD 612 AND THE UTILIZATION THEREOF
ABSTRACT Saccharomyces FD 612 is very useful as a baker's yeast which has been produced by many selections and matings started from three kinds of yeasts, since it has an excellent freeze-resistance and can produce bread with a good quality even after the freeze-storage of a dough.
